BMS/Pfizer’s Eliquis On Priority Review Path Toward March 2012 Approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Priority review designation for the Factor Xa inhibitor suggests FDA sees it as a major treatment advance over Pradaxa and Xarelto in reducing the risk of stroke among atrial fibrillation patients.
You may also be interested in...
NME Candidates For 2012 Have Modest Ambitions; Standard Reviews And Small Molecules Dominate
With the same range of novel product submissions as in 2011, the year ahead could reach an equally healthy tally of new molecular and novel biological entity approvals. But a look at upcoming applications suggests that the makeup of those classes could be very different.
NME Candidates For 2012 Have Modest Ambitions; Standard Reviews And Small Molecules Dominate
With the same range of novel product submissions as in 2011, the year ahead could reach an equally healthy tally of new molecular and novel biological entity approvals. But a look at upcoming applications suggests that the makeup of those classes could be very different.
Bristol/Pfizer's Apixaban Shows Mortality Benefit In ARISTOTLE, But Is It Enough To Supplant Warfarin?
New England Journal of Medicine editorial says cost-effectiveness data and head-to-head studies on new oral anticoagulants are needed to move prescribing away from warfarin for atrial fibrillation patients.